Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study

Therapeutic Advances in Cardiovascular Disease

Volumn 4, Issue 4, 2010, Pages 209-221

  Punzi, Henry ^a   Neutel, Joel M ^b   Kereiakes, Dean J ^c   Shojaee, Ali ^d   Waverczak, William F ^d   Dubiel, Robert ^d   Maa, Jen Fue ^d  

^a Punzi Medical Center   (United States)

^b Orange County Research Center   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d DAIICHI SANKYO INC   (United States)

Author keywords

Ambulatory blood pressure monitoring; Amlodipine; Hypertension; Olmesartan medoxomil

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS OLMESARTAN MEDOXOMIL; ANTIHYPERTENSIVE AGENT; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACKACHE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRONCHITIS; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPESTHESIA; HYPOTENSION; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; ORTHOSTATIC HYPERTENSION; PARESTHESIA; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASODILATOR AGENTS;

EID: 77955396612     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944710374745     Document Type: Article

References (35)

1. Balamuthusamy, S., Srinivasan, L., Verma, M., Adigopula, S., Jalandara, N., Hathiwala, S. et al. (2008) Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 155: 791-805.
2. Bangalore, S., Kamalakkannan, G., Parkar, S. and Messerli, F.H. ( 2007) Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120: 713-719.
3. Basile, J. ( 2004) The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens (Greenwich) 6: 621-629.
4. Campbell, N.R., Khan, N.A., Hill, M.D., Tremblay, G., Lebel, M., Kaczorowski, J. et al. (2009) 2009 Canadian Hypertension Education Program recommendations: the scientific summary-an annual update. Can J Cardiol 25: 271-277.
5. Chavanu, K., Merkel, J. and Quan, A.M. ( 2008) Role of ambulatory blood pressure monitoring in the management of hypertension. Am J Health Syst Pharm 65: 209-218.
6. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr, J.L. et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 289: 2560-2572.
7. Chrysant, S.G., Melino, M., Karki, S., Lee, J. and Heyrman, R. ( 2008) The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 30: 587-604.
8. Chrysant, S.G., Oparil, S., Melino, M., Karki, S., Lee, J. and Heyrman, R. (2009) Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich) 11: 475-482.
9. Cushman, W.C., Ford, C.E., Cutler, J.A., Margolis, K.L., Davis, B.R., Grimm, R.H. et al. (2002) Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens (Greenwich) 4: 393-404.
10. Elliott, W.J. ( 2008) What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich) 10: 20-26.
11. Gosse, P., Lasserre, R., Minifie, C., Lemetayer, P. and Clementy, J. ( 2004) Blood pressure surge on rising. J Hypertens 22: 1113-1118.
12. Jamerson, K., Bakris, G.L., Dahlof, B., Pitt, B., Velazquez, E., Gupte, J. et al. (2007) Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 16: 80-86.
13. Jamerson, K., Weber, M.A., Bakris, G.L., Dahlof, B., Pitt, B., Shi, V. et al. (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359: 2417-2428.
14. Jamerson, K.A., Nwose, O., Jean-Louis, L., Schofield, L., Purkayastha, D. and Baron, M. ( 2004) Initial angiotensin-converting enzyme inhibitor / calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 17: 495-501.
15. Jinno, T., Iwai, M., Li, Z., Li, J.M., Liu, H.W., Cui, T.X. et al. (2004) Calcium channel blocker azelnidipine enhances vascular protective effects of AT 1 receptor blocker olmesartan. Hypertension 43: 263-269.
16. Kuschnir, E., Acuna, E., Sevilla, D., Vasquez, J., Bendersky, M., Resk, J. et al. (1996) Treatment of patients with essential hypertension: amlodipine 5 mg / benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther 18: 1213-1224.
17. Lee, V.C., Rhew, D.C., Dylan, M., Badamgarav, E., Braunstein, G.D. and Weingarten, S.R. ( 2004) Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141: 693-704.
18. Lloyd-Jones, D.M., Evans, J.C. and Levy, D. ( 2005) Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 294: 466-472.
19. Mancia, G., de Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G. et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25: 1105-1187.
20. Muller, J.E., Tofler, G.H. and Stone, P.H. ( 1989) Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79: 733-743.
21. Neutel, J.M., Saunders, E., Bakris, G.L., Cushman, W.C., Ferdinand, K.C., Ofili, E.O. et al. (2005) The efficacy and safety of low- and high-dose fixed combinations of irbesartan / hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE Trial. J Clin Hypertens (Greenwich) 7: 578-586.
22. Okonofua, E.C., Simpson, K.N., Jesri, A., Rehman, S.U., Durkalski, V.L. and Egan, B.M. ( 2006) Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 47: 345-351.
23. Philipp, T., Smith, T.R., Glazer, R., Wernsing, M., Yen, J., Jin, J. et al. (2007) Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 29: 563-580.
24. Pickering, T.G., Hall, J.E., Appel, L.J., Falkner, B.E., Graves, J., Hill, M.N. et al. (2005) Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111: 697-716.
25. Pickering, T.G. and White, W.B. ( 2008) ASH Position Paper: home and ambulatory blood pressure monitoring. When and how to use self (home) and ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 10: 850-855.
26. Punzi, H.A. ( 1998) Why ambulatory blood pressure monitoring? Am J Health Syst Pharm 55(Suppl 3): S12-S16.
27. Rohatagi, S., Carrothers, T.J., Kshirsagar, S., Khariton, T., Lee, J. and Salazar, D. ( 2008) Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. J Clin Pharmacol 48: 823-836.
28. Rosamond, W., Flegal, K., Furie, K., Go, A., Greenlund, K., Haase, N. et al. (2008) Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117: e25-e146.
29. Schrader, J., Salvetti, A., Calvo, C., Akpinar, E., Keeling, L., Weisskopf, M. et al. (2009) The combination of amlodipine / valsartan 5 / 160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract 63: 217-225.
30. Staessen, J.A., Wang, J.G. and Thijs, L. ( 2001) Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358: 1305-1315.
31. Volpe, M., Brommer, P., Haag, U. and Miele, C. (2009) Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 29: 11-25.
32. Weber, M.A., Julius, S., Kjeldsen, S.E., Brunner, H.R., Ekman, S., Hansson, L. et al. (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 363: 2049-2051.
33. Weir, M.R. ( 2003) Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 5: 330-335.
34. Yusuf, S., Diener, H.C., Sacco, R.L., Cotton, D., Ounpuu, S., Lawton, W.A. et al. (2008 a) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359: 1225-1237.
35. Yusuf, S., Teo, K., Anderson, C., Pogue, J., Dyal, L., Copland, I. et al. (2008 b) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372: 1174-1183.